Trial record 20 of 107 for:    "Craniofacial Abnormalities" OR "Baller-Gerold syndrome"

Genetics and Psychopathology in the 22q11 Deletion Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2004 by UMC Utrecht.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Netherlands Brain Foundation
Children's Hospital of Philadelphia
Information provided by:
UMC Utrecht
ClinicalTrials.gov Identifier:
NCT00161109
First received: September 8, 2005
Last updated: October 12, 2006
Last verified: October 2004
  Purpose

The purposes of this study are to:

  1. study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and
  2. identify genes that contribute to the occurrence of these symptoms.

Condition
Chromosome 22q11.2 Deletion Syndrome

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Genetics and Psychopathology in the 22q11 Deletion Syndrome

Resource links provided by NLM:


Further study details as provided by UMC Utrecht:

Estimated Enrollment: 175
Study Start Date: October 2002
Estimated Study Completion Date: October 2012
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   8 Years to 20 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 22q11.2 deletion confirmed with fluorescence in-situ hybridization (FISH)

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00161109

Contacts
Contact: Jacob AS Vorstman, M.D. 215 590 3863 J.A.S.Vorstman@azu.nl

Locations
United States, Pennsylvania
Children's Hospital of Philadelphia, Dpt of Genetics and Dpt of Child and Adolescent Psychiatry Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Jacob AS Vorstman, M.D.    215-590-2862    vorstman@email.chop.edu   
Netherlands
UMC Utrecht, Dpt of Child and Adolescent Psychiatry Recruiting
Utrecht, Netherlands, 3508 GA
Contact: Herman van Engeland, M.D., Ph.D.    +31 30 2506362    H.HaismaPieterse@umcutrecht.nl   
Sponsors and Collaborators
UMC Utrecht
Netherlands Brain Foundation
Children's Hospital of Philadelphia
Investigators
Study Director: René S. Kahn, M.D., Ph.D. UMC Utrecht, The Netherlands
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00161109     History of Changes
Other Study ID Numbers: P03.0377C
Study First Received: September 8, 2005
Last Updated: October 12, 2006
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by UMC Utrecht:
22q11.2 deletion syndrome
Psychopathology
Psychiatry
Neuropsychology
Psychiophysiology
Autism
Psychosis
Deletion size
Candidate genes
Psychiatric symptoms
Neuropsychological impairments
Psychophysiological performance

Additional relevant MeSH terms:
Craniofacial Abnormalities
DiGeorge Syndrome
22q11 Deletion Syndrome
Musculoskeletal Abnormalities
Musculoskeletal Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Lymphatic Abnormalities
Lymphatic Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Hypoparathyroidism
Parathyroid Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 23, 2014